

April 20, 2023

## BELLUS Health Inc. Reaches Agreement for US\$2-Billion Sale to GSK

Davies is acting as counsel to BELLUS Health, Inc. in its US\$2-billion sale to GSK, a global pharmaceutical company headquartered in the United Kingdom.

Based in Montréal, BELLUS Health works to better the lives of patients suffering from refractory chronic cough (RCC) that does not respond to treatment for an underlying condition or is otherwise unexplained.

The acquisition provides GSK with access to camlipixant, a potential best-in-class and highly selective P2X3 antagonist developed by BELLUS Health. Camlipixant is currently in phase III development for the first-line treatment of adult patients with RCC. The acquisition also complements GSK's expertise in respiratory medicines and enhances its leading R&D, manufacturing and commercialization capabilities.

The transaction is expected to close in the third quarter of 2023 or earlier.

The Davies team advising on the transaction includes Sébastien Roy, Amélie Doyon and Ryan Brun (Corporate and Public M&A); Brian Bloom and Taj Kudhail (Tax); Charles Tingley (Competition, Antitrust and Foreign Investment); Hélène Bussières (Employment, Labour and Executive Compensation); and Louis-Martin O'Neill and Faiz Lalani (Dispute Resolution).